亚盛医药董事局主席、CEO为杨大俊博士,非执行董事分别为王少萌博士、吕大忠博士;独立非执行董事分别为叶长青、任为、DavidSidransky博士。 IPO前,杨大俊等管理层控制19.2%股权,TakedaPharmaceuticals持股为7.71%; IPO后,管理层控制17.5%股权,TakedaPharmaceuticals持股为7.1%; 以下是亚盛医药路演PPT: ——— 雷递由媒体人...
作者: 1/21,亚盛医药(Ascentage Pharma)计划通过在纳斯达克首次公开募股(IPO)筹集近1.49亿美元,成为今年首家寻求赴美上市的主要中国企业。该癌症药物开发商于2019年在香港上市,此次目标估值为17.5亿美元,拟以每股20.34美元的价格发行730万份美国存托股票(ADS),每份ADS代表四股普通股。 此次募资计划距亚盛医药与武田(T...
1/21,亚盛医药(Ascentage Pharma)计划通过在纳斯达克首次公开募股(IPO)筹集近1.49亿美元,成为今年首家寻求赴美上市的主要中国企业。该癌症药物开发商于2019年在香港上市,此次目标估值为17.5亿美元,拟以每股20.34美元的价格发行730万份美国存托股票(ADS),每份ADS代表四股普通股。此次募资计划距亚盛医药与武田(Takeda)签订...
Ascentage Pharma and Takeda, a multinational pharmaceutical company, have entered into an exclusive option agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for olverembatinib. Once exercised, the Option would allow Takeda to license global rights to deve...
Ascentage is one such beneficiary, having licensed olverembatinib to Takeda last year. Dive Insight: Ascentage’s Wall Street debut is a test of U.S. investors’ interest in the progress China’s biotech sector has made. Efforts by the Chinese government to boost the country’s capabilities ...
See “Business—License, collaboration and other agreements—Takeda exclusive option agreement.” Our second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor that we are developing for the treatment of various hematological malignancies. In November 2024, we announced that our NDA for the ...
Ascentage Pharmahas built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies such as Takeda, AstraZeneca, Merck, Pfizer and Innovent; and research and development relationships with ...
Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies such as Ta...
Jul 4 21:55 ASCENTAGE-B: VOLUNTARY ANNOUNCEMENT - OPTION PAYMENT RECEIVED UNDER THE EXCLUSIVE OPTIONAGREEMENT WITH TAKEDA Jul 4 07:12 ASCENTAGE-B: Next Day Disclosure Return Jun 21 07:05 ASCENTAGE-B: CLOSING OF ISSUANCE OF NEW SHARESUNDER GENERAL MANDATE Jun 21 07:00 Load More ...
Takeda-backed Ascentage Pharma sets terms for $170M IPOSA NewsTue, Jan. 21 Ascentage Pharma Group International reports 1H resultsSA NewsFri, Aug. 26, 2022 ASPHF Company Profile Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic he...